Goodwin Releases Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.

New publication is a go-to reference on all things biosimilars

Goodwin has released its Guide to Biosimilars Litigation and Regulation in the U.S., 2022-2023 ed., a comprehensive reference guide authored by a group of lawyers from Goodwin’s Intellectual PropertyLife SciencesFDAProducts Litigation + CounselingAntitrust + Competition and Appellate Litigation practices and published by Thomson Reuters.

To purchase from Thomson Reuters, click here.

Other Publications

Below is a sampling of articles and other publications authored by members of the Big Molecule Watch blog team and other Goodwin attorneys and law clerks on issues relating to biosimilars, pharma or biotech more generally.


*Former Goodwin attorney
**Law clerk